Dapagliflozin in Respiratory Failure in Patients With COVID-19

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2020
This is an international, multicenter, parallel-group, randomized, double-blind, placebo controlled, study in hospitalized adult patients with coronavirus disease 2019 (COVID-19) in the United States, Brazil, Mexico, Argentina, India, Canada, and United Kingdom. The study is evaluating the effect of dapagliflozin 10 milligrams versus placebo, given once daily for 30 days in addition to background local standard of care therapy, on reducing complications and all-cause mortality, or improving clinical recovery.
Epistemonikos ID: 9b41ca19a3fb3d3f23d1896bea2eaa8a3d00b589
First added on: Apr 18, 2020